



Molecular Biomarkers for Risk and Prognosis of Cancer

Guest Editor:

Dr. Lang Wu

Cancer Epidemiology Division,
Population Sciences in the
Pacific Program, University of
Hawaii Cancer Center, University
of Hawaii at Manoa, Honolulu, HI
96813, USA

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editor

Dear Colleagues,

There are critical needs to identify and validate novel biomarkers for risk and prognosis of different cancers aiming to reduce public health burden of human malignancies. Biomarkers can be at different layers, for example, genetic variants, genes, CpG sites, proteins, metabolites, glycans, micro-RNAs, etc., using body fluids such as blood or other tissues. With the development of high-throughput technologies, it is now possible to screen the human genome, transcriptome, proteome, metabolome, glycome, etc. in an agnostic way to identify novel biomarker candidates for cancers. There are also emerging new strategies integrating genomics and other types of -omics data in uncovering novel biomarker candidates. It is also an attractive area of using newly identified biomarkers for risk and prognosis prediction of human malignancies.

In this Special Issue, we will publish original research and review articles that provide new insights into the role of different layers of biomarkers for risk and prognosis of different malignancies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)